Related Experiment Video

Updated: Jan 2, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.9K

Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Mubalake Abudoureyimu1, Yongting Lai2, Chuan Tian1

  • 1Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.

Frontiers in Oncology
|November 30, 2019
PubMed

Insights

Gene-targeted oncolytic viral therapy (GTOVT) shows promise for treating hepatocellular carcinoma (HCC). Engineering oncolytic adenoviruses and modulating immune responses are key to improving HCC treatment efficacy.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent cancer globally, with poor survival rates despite current treatments.
  • Gene-targeted oncolytic viral therapy (GTOVT) represents an emerging strategy using engineered viruses to combat cancer.

Purpose of the Study:

  • To review recent advancements in engineering oncolytic adenoviruses for HCC treatment.
  • To discuss novel therapeutic genes used in conjunction with oncolytic adenoviruses.
  • To explore the role of host immune responses in GTOVT efficacy and strategies for immune modulation.

Main Methods:

  • Review of current literature on oncolytic adenovirus engineering.
  • Analysis of novel therapeutic genes for HCC gene-targeted oncolytic viral therapy.
  • Discussion of immunological aspects and modulation strategies in oncolytic adenovirus therapy.

Main Results:

  • Oncolytic adenoviruses are promising vectors for GTOVT due to their inherent advantages.
  • Engineering efforts focus on enhancing viral vectors and incorporating effective anti-cancer genes.
  • Host immune response significantly influences therapeutic outcomes, necessitating immune modulation strategies.

Conclusions:

  • Oncolytic adenovirus engineering and the strategic use of therapeutic genes are advancing HCC treatment.
  • Understanding and modulating the immune response is crucial for maximizing the anti-cancer efficacy of oncolytic adenoviruses.
  • GTOVT holds significant potential as a future therapeutic approach for hepatocellular carcinoma.
Keywords:
HCCadenovirusgene-targeted oncolytic viral therapyimmunotherapyvirus engineering

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K